Dear Editor,
We read with great interest, the article entitled 'Comparison of two interferon-gamma release assays (QuantiFERON-TB Gold In-Tube and T-SPOT.TB) in testing for latent tuberculosis infection among HIV-infected adults' by Sultan et al., 1 which indicated that the QuantiFERON-TB Gold In-Tube (QFT-IT) was suitable for diagnosing latent tuberculosis (LTBI) in HIV-infected patients who received antiretroviral therapy (ART) and had good CD4 cell counts. The study also showed that indeterminate results were due to low CD4 cell counts, less than 200 cells/ml. Their work contributed to the evidence base for use of QFT-IT for detection of LTBI in HIV-infected patients in the UK.
We would like to share our recent experience of 70 patients tested by QFT-IT. In our study, eight patients with clinical symptoms of TB, including fever and productive cough, confirmed by sputum culture and chest radiography, had a positive QFT-IT result (positive rate 100%). Among 62 patients without clinical symptoms, 36 patients were negative by QFT-IT, 25 patients were indeterminate, and only one was positive who was confirmed with LTBI subsequently. As far as the patients with indeterminate results were concerned, the median CD4 cell count was always less than 200 cells/ml, which was similar to previous reports. [1] [2] [3] In conclusion, the QFT-IT could be a potential, simple and feasible method for diagnosing and screening TB in HIV-infected patients. The patients' CD4 cells count is an important influential factor when interpreting the results of QFT-IT.
